Autolus (AUTL) Q4 2025 earnings review
Steady US Launch Maturation Paired with Major UK Regulatory Reversal
Autolus capped off its first full commercial year with $23.3M in Q4 AUCATZYL net product revenue, bringing the FY25 total to $74.3M. While sequential US revenue growth decelerated in the second half of the year, the real breakthrough comes from Europe: following previous reimbursement headwinds, Autolus secured a successful NICE evaluation and officially launched AUCATZYL in the UK in January 2026. Profitability remains an issue as Q4 Cost of Sales ($25.3M) exceeded revenue, driving a $90.3M net loss. However, decreasing quarterly COGS and strong FY26 revenue guidance ($120M-$135M) suggest the company is finally on the precipice of achieving positive gross margins.
🐂 Bull Case
After a preliminary negative appraisal from NICE in mid-2025, management successfully navigated negotiations. The resulting UK launch in January 2026 adds a substantial new revenue vector that was previously assumed zero for 2025/2026.
The ROCCA consortium database (covering ~60% of US commercial patients) confirms AUCATZYL's strong safety profile, reporting only a 3% rate of high-grade ICANS. This real-world validation is critical for driving physician adoption and deeper center penetration.
🐻 Bear Case
While total FY25 revenue was solid, QoQ growth flattened significantly in the second half of the year ($20.9M in Q2 -> $21.1M in Q3 -> $23.3M in Q4), raising questions about peak penetration rates within the initial ~60 activated US treatment centers.
Despite revenue growth, Q4 COGS still exceeded sales, and the company burned through $287.3M in cash/marketables over the course of 2025. If the manufacturing optimization initiatives fail, runway could become tight before the 2027 pipeline readouts.
⚖️ Verdict: 🟢
Bullish. The UK launch clearance is a massive, unexpected win that changes the near-term revenue trajectory. Combined with real-world validation of AUCATZYL's safety profile and a clear, accelerating pipeline into autoimmune disease, the commercial foundation is solidifying.
Key Themes
Surprise NICE Approval Triggers UK Launch
Reversing previous setbacks. In Q2 2025, Autolus guided for $0 in EU/UK sales for 2025 and 2026 due to systemic reimbursement hurdles. The Q4 update reveals a successful National Institute for Health and Care Excellence (NICE) evaluation, with routine commissioning and launch in the UK already underway as of January 2026. This opens a large, previously discounted market.
Persistent Negative Gross Margins
Stable but still negative. Q4 marked the fourth consecutive quarter where Cost of Sales exceeded Product Revenue. Q4 COGS of $25.3M outpaced revenue of $23.3M, driven by cancelled orders, patient access programs, and inventory write-offs. Management claims Q4 initiated a new manufacturing life cycle plan aiming to finally cross into positive gross margins in 2026.
Autoimmune Pipeline 'Pipeline in a Product' Accelerates
Autolus is rapidly diversifying beyond oncology. Following promising early CARLYSLE Phase 1 data in severe systemic lupus erythematosus (SLE) showing deep B-cell depletion without ICANS, the pivotal LUMINA trial in lupus nephritis is actively enrolling. Additionally, the first patient was dosed in the BOBCAT Phase 1 trial for progressive MS. This represents a strategic pivot toward much larger addressable markets.
Decelerating Sequential Sales Growth
Decelerating. After a massive jump from Q1 ($9.0M) to Q2 ($20.9M), the sequential growth rate cratered. Q3 posted $21.1M, and Q4 saw only a modest bump to $23.3M. Management must prove that this plateau is a temporary launch artifact rather than an early ceiling in adult r/r B-ALL market penetration.
ROCCA Database Validates Outpatient Potential
Initial real-world data from the ROCCA consortium is extremely favorable. Covering roughly 60% of US commercial patients, the data aligns with the original FELIX trial, notably reporting only a 3% incidence of high-grade ICANS. This highly manageable safety profile is Autolus's primary weapon against entrenched competitors and a critical lever for expanding into outpatient settings.
Other KPIs
Down from $588.0 million at the end of 2024. The company burned approximately $287 million in 2025. While management expects this balance to fund operations into Q4 2027, the heavy burn rate highlights the necessity of achieving positive gross margins and growing the top line aggressively in 2026.
For the full year 2025, SG&A surpassed R&D expenses as commercialization headcount ballooned to support the US rollout. Q4 SG&A was $35.8M compared to R&D at $35.6M, illustrating the shift from a pure development stage company to a commercial organization.
Guidance
Accelerating. The midpoint of $127.5M implies ~71% YoY growth over the FY25 total of $74.3M. This robust outlook likely factors in the newly announced UK launch and deeper penetration within established US treatment centers.
Reversing. After posting a negative gross profit for the entirety of FY25 (cumulative COGS of $96.4M vs Product Rev of $74.3M), management explicitly guides to a positive gross margin in 2026, driven by higher manufacturing plant utilization and the newly initiated manufacturing life cycle optimization plan.
Stable. The company reiterates its expectation that current liquidity of $300.7 million will last into late 2027, providing sufficient buffer to report pivotal data from LUMINA (lupus nephritis) and CATULUS (pediatric ALL) without requiring an immediate equity raise.
Key Questions
Gross Margin Bridge
You guided to positive gross margins in 2026. What specific cost levers within the new 'manufacturing life cycle plan' give you the most confidence to flip profitability, and how much of this assumes reduced out-of-spec or inventory write-offs vs. raw volume absorption?
UK Pricing and Launch Dynamics
With the successful NICE evaluation and UK launch underway, how should we model the pricing and reimbursement economics in the UK compared to the US, and will this trigger further European rollouts?
QoQ Revenue Plateau
US revenue growth was relatively flat between Q2, Q3, and Q4. Has AUCATZYL reached a near-term ceiling within the current activated centers, or were there specific Q4 operational bottlenecks limiting patient throughput?
BOBCAT Enrollment Speed
As you expand into the much larger multiple sclerosis market with BOBCAT, what are the early indicators on patient recruitment speed compared to your oncology trials?